The U.S. Senate and the U.S. House of Representatives are both considering legislation that could have a serious impact on the ability of U.S. biotechnology, drug, and medical device companies to do business with...more
3/19/2024
/ Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
China ,
Department of Homeland Security (DHS) ,
Life Sciences ,
Medical Devices ,
National Security ,
OMB ,
Pharmaceutical Industry ,
Popular ,
Risk Assessment